Author: Melissa Pozotrigo, PharmD, BCOP Minimal residual disease (MRD) testing has become one of the most important advances in cancer care over the past twenty years. It can find very small amounts of remaining disease that standard methods such as blood tests,...
Cancer care is often measured in clinical milestones such as diagnosis, treatment, and remission. But for many individuals, the experience extends beyond physical care. Mental health concerns are common, complex, and closely connected to overall outcomes. Research...
Genetic and molecular testing is transforming oncology care, but it is also introducing a new layer of complexity, cost, and clinical risk for health plans. In 2024, Medicare Part B spending on human genetic tests surpassed $2 billion for the first time, according...
For years, health plan oncology strategy has focused primarily on cancer treatment using tools like prior authorization, clinical pathways, drug preference mandates, and site-of-care optimization. While these remain critical, they are no longer sufficient on their...
Author: Corey Wise, RPh, M.S., BCOP, Senior Clinical Oncology Pharmacist, OncoHealth Health insurance premiums are projected to see their largest increase in 15 years — and rising cancer rates among working-age adults are partly to blame. Here’s how prevention and...
Why Nutrition Deserves More Attention from Health Plans Malnutrition in cancer care is more than a clinical issue; it’s a financial one. According to the National Cancer Institute, 30% to 85% of people with cancer do not get enough nutrients or calories to support...
